Filing Manager
Deep Track Capital, LP
Reporting Manager
Deep Track Capital, LP
Shares outstanding
22,502,040 shares
Disclosed Ownership
3,352,804 shares
Ownership
15%
Form type
SCHEDULE 13D
Filing time
19 Sep 2025, 16:30:03 UTC
Date of event
12 Sep 2025
Previous filing
10 Feb 2026

Quoteable Key Fact

"Deep Track Capital, LP disclosed 15% ownership in LB Pharmaceuticals Inc Common Stock, $0.0001 par value per share on 12 Sep 2025."

Quick Takeaways

  • Deep Track Capital, LP filed SCHEDULE 13D for LB Pharmaceuticals Inc Common Stock, $0.0001 par value per share.
  • Disclosed ownership: 15%.
  • Date of event: 12 Sep 2025.

What Changed

  • Previous schedule filing date: 10 Feb 2026.
  • Current filing was accepted on 19 Sep 2025, 16:30.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Deep Track Biotechnology Master Fund, Ltd. 12% 2,686,138 0 2,686,138 /s/ David Kroin David Kroin, Director
Deep Track Special Opportunities Fund, LP 3% 666,666 0 666,666 /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Manager
Deep Track Capital, LP 15% 3,352,804 0 3,352,804 /s/ David Kroin David Kroin, Managing Member of the General Partner 0001856083
David Kroin 15% 3,352,804 0 3,352,804 /s/ David Kroin David Kroin
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .